Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 418-425 , April 2008

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome

  • Philippe Armand

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Philippe Armand, MD, PhD, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115.
    • ,
  • Haesook T. Kim

      Affiliations

    • Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Vincent T. Ho

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Corey S. Cutler

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • John Koreth

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Joseph H. Antin

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Ann S. LaCasce

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Eric D. Jacobsen

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • David C. Fisher

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Jennifer R. Brown

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • George P. Canellos

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Arnold S. Freedman

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Robert J. Soiffer

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Edwin P. Alyea

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Received 7 January 2008 ,Accepted 29 January 2008.

References 

  1. Schmitz N, Dreger P, Glass B, Sureda A. Allogeneic transplantation in lymphoma: current status. Haematologica. 2007;92:1533–1548
  2. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–678
  3. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529
  4. Bierman PJ, Sweetenham JW, Loberiza FR, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21:3744–3753
  5. Khouri IF, Saliba RM, Lee M-S, et al. Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation (NMT) for non-Hodgkin's lymphoma (NHL), including patients with PET or gallium-avid disease. Blood. 2005;106:44
  6. Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006;12:1056–1064
  7. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  8. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  9. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1140–1154
  10. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
  11. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35:943–951
  12. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol. 1993;11:2342–2350
  13. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291–1296
  14. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol. 2001;19:4314–4321
  15. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865–3871
  16. Maris MB, Sandmaier BM, Storer B, et al. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. (ASH Annual Meeting Abstracts). Blood. 2005;106:1130
  17. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev. 2006;20:235–244
  18. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;
  19. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2007;
  20. Baron F, Storb R, Storer B, et al. Allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning after failed myeloablative HCT: factors affecting outcomes. (ASH Annual Meeting Abstracts). Blood. 2005;106:1143
  21. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310–4316
  22. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103:428–434
  23. Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131:223–230
  24. Kiss TL, Mollee P, Lazarus HM, Lipton JH. Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplant. 2005;36:655–661
  25. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535–3542
  26. Robinson SP, Schmitz N, Taghipour G, Sureda A. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemoresistant disease. (ASH Annual Meeting Abstracts). Blood. 2004;104:2260

PII: S1083-8791(08)00051-7

doi: 10.1016/j.bbmt.2008.01.008

Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 418-425 , April 2008

Article Tools

* Image Usage & Resolution